Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Latest Developments in Cell and Gene Therapy Manufacturing Cell and gene therapies are rapidly emerging as one of the most transformative areas in modern medicine. These advanced therapies aim t...
